Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Rallybio is a clinical-stage biotechnology company focused on developing and commercializing novel therapeutics for patients with severe and rare diseases. The company leverages its deep expertise in drug development and a collaborative approach to identify promising drug candidates and advance them through clinical trials. Rallybio's mission is to make a meaningful impact on the lives of individuals affected by these debilitating conditions by delivering innovative treatments where significant unmet medical needs exist. They aim to build a portfolio of therapies targeting various rare diseases, driven by scientific rigor and a patient-centric philosophy.
Serves as the central hub for Rallybio's corporate management, strategic planning, research and development oversight, financial operations, and administrative functions.
Located within 'The Exchange,' a modern life sciences campus, offering state-of-the-art laboratory and office facilities. Its proximity to research institutions and talent pools in Connecticut is a key feature.
Rallybio fosters a work culture centered on innovation, collaboration, urgency, and a profound commitment to patients with rare diseases. It's likely characterized by scientific rigor, agility, and a team-oriented approach to tackling complex challenges in drug development.
The Farmington headquarters strategically places Rallybio within Connecticut's burgeoning bioscience corridor, facilitating access to specialized talent, academic collaborations (like nearby UConn Health), and a supportive ecosystem. It is pivotal for their R&D leadership and corporate decision-making.
Rallybio manages global clinical trials for its therapeutic candidates, requiring coordination across multiple countries. Its registered entity in Dublin, Ireland (Rallybio Group Limited) signifies a strategic European presence, important for regulatory interactions, clinical trial oversight, and potential future market access in the region. The company collaborates with international researchers and patient advocacy groups to advance its mission for rare diseases worldwide.
400 Farmington Avenue
Farmington
CT
USA
Address: 234 Church Street, Suite 1020, New Haven, CT 06510
Facilitates collaboration with local research institutions, access to specialized talent in the New Haven biotech hub, and supports R&D and business development activities.
Address: Rallybio Group Limited, Regus, Harcourt Centre, Dublin 2, D02 HW77
Establishes a corporate presence in the EU, crucial for managing aspects of European clinical trials, engaging with regulatory authorities like the EMA, and preparing for potential future commercial activities in Europe.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Rallybio' leadership includes:
Rallybio has been backed by several prominent investors over the years, including:
Over the past year, Rallybio has significantly strengthened its executive leadership team with key strategic appointments. The company onboarded a new Chief Medical Officer and a new Chief Development Officer, underscoring its commitment to advancing its clinical pipeline and enhancing its drug development capabilities. These hires bring valuable expertise in rare diseases and clinical operations.
Discover the tools Rallybio uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Rallybio commonly uses the email format of the employee's first initial followed by their last name. This is a standard convention in many corporations, particularly within the biotechnology and pharmaceutical sectors.
[first_initial][last]@rallybio.com
Format
mmackay@rallybio.com
Example
85%
Success rate
GlobeNewswire • May 9, 2024
Rallybio announced its financial results for the first quarter of 2024 and provided updates on its clinical programs, including progress on RLYB212 for preventing Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) and RLYB116 for complement-mediated diseases....more
GlobeNewswire • March 26, 2024
Rallybio announced the dosing of the first participant in its Phase 2 globally-conducted clinical study evaluating RLYB212, an anti-HPA-1a monoclonal antibody, for the prevention of FNAIT....more
GlobeNewswire • January 4, 2024
Rallybio outlined its key strategic priorities for 2024, focusing on advancing its clinical pipeline, particularly RLYB212 for FNAIT prevention and RLYB116 for complement-mediated diseases, and managing its capital resources....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Rallybio, are just a search away.